- West Pharma’s adjusted earnings per share (EPS) for the first quarter is $1.45, higher than the estimated $1.23, but lower than last year’s $1.56.
- Net sales reached $698.0 million, showing a slight increase of 0.4% compared to last year, surpassing the estimate of $685.8 million.
- Sales of Proprietary Products were $563.0 million, marking a 0.6% rise year-over-year and beating the expected $555.6 million.
- Contract Manufacturing sales were slightly down by 0.7% year-over-year to $135.0 million, although they exceeded the estimated $129.2 million.
- Organic sales saw an increase of 2.1%.
- The company reported an adjusted operating income of $125.0 million, a 1.6% increase from last year, and above the forecasted $109 million.
- The current recommendation includes 12 buys, 3 holds, and 0 sells for West Pharma’s stock.
West Pharmaceutical Services Inc on Smartkarma
Analysts on Smartkarma, such as Baptista Research, are closely monitoring West Pharmaceutical Services Inc. Baptista Research recently published research reports on the company, delving into key insights and sentiment towards West Pharmaceutical Services.
One report titled “West Pharmaceutical Services: How GLP-1 and Biologics Are Unlocking Explosive Growth!” highlighted the company’s financial results for the fourth quarter and full year 2024. Meanwhile, another report, “West Pharmaceutical Services: Expanding Capacity in High-Value Product Lines & Unlocking Commercial Manufacturing Potential! – Major Drivers,” discussed third-quarter earnings and strategic initiatives driving performance. Baptista Research is actively evaluating factors that could impact the company’s stock price, utilizing methodologies like the Discounted Cash Flow model for independent valuation.
A look at West Pharmaceutical Services Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 2.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, West Pharmaceutical Services Inc has a mixed long-term outlook. While the company shows resilience and moderate growth potential, its value and dividend scores are average. The company’s focus on bringing new drug therapies to global markets through value-added services positions it well in the industry.
West Pharmaceutical Services, Inc. is dedicated to providing essential services for the healthcare sector, focusing on packaging components, drug delivery systems, and contract laboratory services. With a resilient outlook and potential for growth, the company continues to play a vital role in the global healthcare market.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
